ODMA/MHODMA/iManage;425434;1

PATENT APPLICAT DOCKET NO.: 2869.1001-023

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Richard A. Young and Douglas Young

Application No.:

10/046,649

Group: 1648

RECEIVED

Filed:

January 14, 2002

Examiner:

Stacy S. Brown

OCT 1 7 2003

Confirmation No.:

3487

TECH CENTER 1600/2900

Title:

STRESS PROTEINS AND USES THEREFOR

CERTIFICATE OF MAILING OR TRANSMISSION  I hereby certify that this correspondence is being deposited with the United States
Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:
Date Signature
Typed or printed name of person signing sertificate

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

(Filed after payment of issue fee)

10/16/2003 NROCHO1 00000011 10046649

.00 OP

Sir:		10) 10) E000 tutoutus - 0	
	Information Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)	01 FC:1886	180.09 Q
[ ]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national a stage in an international application; or before the mailing date of a first office a CPA, or a Request for Continued Examination).	pplication (other than a CPA) or datection on the merits in a non-provision	te of entry of the national onal application, including a
[X]	under 37 CFR 1.97(c) together with either:  [ ] a Statement under 37 CFR 1.97(e), as checked	halass s	
	[X] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowa		
[ ]	under 37 CFR 1.97(d) together with:		
	[ ] a Statement under 37 CFR 1.97(e), as checked	below, and	
	[ ] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or be	pefore payment of the issue fee)	
. 1	under 37 CFR 1 97(i).	·	

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

[X]

State	ement	<u>Under 37 CFR 1.97(e)</u>
[ ]	Eac	ch item of information contained in this Information Disclosure Statement was first cited in communication from a foreign patent office in a counterpart foreign application not more n three months prior to the filing of this Information Disclosure Statement; or
[ ]	No con kno in tl	item of information contained in this Information Disclosure Statement was cited in a amunication from a foreign patent office in a counterpart foreign application, and, to the wledge of the undersigned, after making reasonable inquiry, no item of information contained information disclosure statement was known to any individual designated in 37 CFR (c) more than three months prior to the filing of this Information Disclosure Statement.
		Jnder 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000
[]	was	n item of information contained in the Information Disclosure Statement was cited in a munication from a foreign patent office in a counterpart application and this communication not received by any individual designated in § 1.56(c) more than thirty days prior to the g of the Information Disclosure Statement.
[X]	Encl	osed herewith is form PTO-1449:
	[X]	Copies of the cited references are enclosed.
		[ ] Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
	[]	Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
	[ ]	The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
	[X]	The "concise explanation" requirement (non-English references) for reference(s) <b>AN4</b> and <b>AY8</b> under 37 CFR 1.98(a)(3) is satisfied by:
		[ ] the explanation provided on the attached sheet.
		[ ] the explanation provided in the Specification.
		[ ] submission of the enclosed International Search Report.
		[ ] submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
		[X] the enclosed English 1

the enclosed English language abstract.

[X]	App	plicant requests that the follow	ing applications be cons	idered:
Exami Initia	ner's Is			
		U.S. Patent Application No filed June 5, 1995, Docket I	o. 08/461,720, by Richard No.: 2869.1001-002 (ABA	A. Young and Douglas Young, NDONED)
			ol No. 90/006 418 by Dia	hard A. Young, filed October 22
	_	U.S. Reexamination Contro 2002, Docket No.: ANT-2 (2	ol No. 90/006,419, by Ricl 2869.1001-041)	nard A. Young, filed October 22,
		Examiner	Date	
	[]	A copy of each above-cited	application, including the	e current claims, is enclosed.
	[]		application, including the	
The I which	Examin 1 refere	er is requested to return a cop ences were considered with the	wofthe show I' ( c	ding applications indicating
		d that the information disclosed		
Metho	od of pa	yment:		
[X]	A chec	ck for the fee noted above is end	closed. A copy of this Stat	ement is enclosed.
[ ]		charge Deposit Account 08-039		]. A copy of this Statement is
[X]	Please	charge any deficiency in fees ar	nd credit any overpayment	to Deposit Account 08-0380.
		I	Respectfully submitted,	
		I	HAMILTON, BROOK, SM	MITH & REYNOLDS, P.C.
		E	Anne J. Collins Registration No.: 40,564 Telephone: (978) 341-003 Facsimile: (978) 341-013	Colling

Concord, MA 01742-9133
Dated: October 10, 2013

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
INFORMATION DISCLOSURE CITATION AN APPLICATION October 10, 2003 See several sheets if necessary)	APPLICANT Richard A. Young, et al.		
	FILING DATE January14, 2002	CONFIRMATION NO. 3487	group 1648

		U.	.S. PATENT DOCUMENTS	
M-	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
+	AA 4	4,716,038	29-Dec-87	Stanford, et al.
-+-		4,724,144	9-Feb-88	Rook, et al.
-+-		5,114,844	19-May-92	Cohen, et al.
<del></del>		5,504,005	2-Apr-96	Bloom, et al.
$\dashv$		6,335,183 B1	1-Jan-02	Cohen, et al.  Bloom, et al.  Young  Young  Kingsmen, et al.  Young  Tam, et al.
-+		6,338,952 B1	15-Jan-02	Young Cy 7
-+	<del>                                     </del>	4,918,166	17-Apr-90	Kingsmen, et all
$\dashv$	<del> </del>	5,580,563 A	3-Dec-96	Tam, et al. 1600/29
$\dashv$	AI	6,482,614 B1	19-Nov-02	Young
$\dashv$	AJ	4,557,931	10-Dec-85	Irie, et al.
	AK	6,030,618	29-Feb-00	Srivastava
$\neg$	AA2	6,455,493 B1	24-Sep-02	Wallen, et al.
	AB2	6,403,099 B1	11-Jun-02	Rappuoli, et al.
— \	AC2	US-2002-0146426-A1	10-Oct-02	Huang, et al.
	AD2	US-2001-0005713-A1	28-Jun-01	Young
	AE2			
	AF2			
	AG2			
_	AH2			
	Al2			
_	AJ2			
_	AK2			
_	AA3			
	AB3			
_	AC3	+		

EXAMINER	DATE CONSIDERED
ODMA AMIODMA/Managa:425369:1	

PTO-1449	REPRODUCED
OIP	MATION DISCLOSURE CITATION IN AN APPLICATION

October 10, 2003

se several sheets if necessary)

ATTORNEY DOCKET NO. 2869.1001-023

APPLICATION NO. 10/046,649

APPLICANT

Richard A. Young, et al.

FILING DATE
January14, 2002

CONFIRMATION NO. 3487

GROUP 1648

$\frac{}{}$		FOREIGN PATENT DO		TRANSLATION
	DOCUMENT NUMBER	DATE	COUNTRY	YES NO
AL	WO88/00974	11-Feb-88	PCT	
AM	WO85/05034	21-Nov-85	PCT	
AN	WO88/05823	11-Aug-88	PCT	
AO	WO88/06591	7-Sep-88	PCT	
AP	WO91/02542	7-Mar-91	PCT	- 8
AQ	WO91/15572	17-Oct-91	PCT	Part of the second of the seco
AL2	WO 92/08484	29-May-92	PCT	CA CA CA
AM2	WO 92/08488	29-May-92	PCT	1000
AN2	0 262 710	7-Sep-87	ЕРО	
AO2	0 322 990	5-Jul-89	ЕРО	
AP2	2 251 186	1-Jul-92	Great Britain	
AQ2	WO 89/12455	28-Dec-89	PCT	
AL3	WO 93/17712	16-Sep-93	PCT	
AM3	WO 94/03208	17-Feb-94	PCT	
AN3	WO 90/15873	27-Dec-90	PCT	
AO3	WO 95/31994	30-Nov-95	PCT	
AP3	WO 95/24923	21-Sep-95	PCT	
AQ3	WO 94/29459	22-Dec-94	PCT	
AL4	WO 97/06821	27-Feb-97	PCT	
AM4	WO 98/23735	4-Jun-98	PCT	
AN4	WO 97/26910	31-Jul-97	PCT	
AO4	WO 96/10421	11-Apr-96	PCT	
AP4	WO 95/24923	21-Sep-95	PCT	
AQ4	WO 98/35705	20-Aug-98	PCT	
AL5	WO 99/07860	18-Feb-99	PCT	
AM5	WO 01/51081	19-Jul-01	PCT	

EXAMINER
----------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
PIETORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT Richard A. Young, et al.	•	
October 10, 2003  Se several sheets if necessary)	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648

1	
STE THE	CONTROL DO CALLADATES (I. I. I Analysis Tide Data Portinant Pages Ftc.)
	OTHER DOCUMENTS (Including Author) Title, Date, 1 criment 1 mg es, 2 criment
AR	Lamb, J.R., et al., "Stress Proteins may Provide a Link Between the Immune Response to Infection and Autoimmunity", Int'l. Immun., 1(2):191-196 (1989).
AS	Young, R. A., "Stress Proteins and Immunology," Annu. Rev. Immunol., 8:401-420 (1990).
АТ	Lussow, A. R. et al., "Mycobacterial heat-shock proteins as carrier molecules," Eur. J. Immunol., 21:2297-2302 (1991).
AU	Barrios, C. et al., "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming," Eur. J. Immunol., 22:1365-1372 (1992).
AV	Blander, S. J. and Horwitz, M. A., "Major Cytoplasmic Membrane Protein of Legionella pneumophila, a Genus Common Antigen and Member of the hsp 60 Family of Heat Shock Proteins, Induces Protective Immunity in a Guinea Pig Model of Legionnaires' Disease," J. Clin. Invest., 91:717-723 (1993).
AW	Del Giudice, G. D., et al., "Priming to Heat Shock Proteins in Infants Vaccinated against Pertussis," J. Immunol., 150(5):2025-2032 (1993).
AX	Agranovsky, A. A., et al., "Putative 65 kDa Protein of Beet Yellows Closterovirus Is a Homologue of HSP70 Heat Shock Proteins," J. Mol. Biol., 217:603-610 (1991).
AY	Miller, A. et al., "Immunotherapy in autoimmune diseases," Curr. Opinion in Immun., 3:936-940 (1991).
AZ	Nadler, S. G. et al., "Interaction of the Immunosupressant Deoxyspergualin with a Member of the Hsp70 Family of Heat Shock Proteins," Science, 258:484-486 (1992).
AR2	Elias, D. et al., "Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein," Proc. Natl. Acad. Sci. USA, 87:1576-1580 (1990).
AS2	Thole, J. E.R. et al., "Characterization, Sequence Determination, and Immunogenicity of a 64-Kilodalton Protein of Mycobacterium bovis BCG Expressed in Escherichia coli K-12," Infection & Immunol., 55(6):1466-1475 (1987).
AT2	Young, R. A. et al., "Genes for the major protein antigens of the leprosy parasite mycobacterium leprae," Nature, 316:450-452 (1985).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
October 10, 2003  Use several sheets if necessary)	APPLICANT Richard A. Young, et al.		
October 10, 2003	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AU2	Husson, R. N. and Young, R.A., "Genes for the major protein antigens of Mycobacterium tuberculosis: The etiologic agents of tuberculosis and leprosy share an immunodominant antigen," Proc. Natl. Acad. Sci. USA, 84:1679-1683 (1987).
AV2	Young, D. et al., "Stress proteins are immune targets in leprosy and tuberculosis," Proc. Natl. Acad. Sci. USA, 85:4267-4270 (1988).
AW2	Lindquist, S. and Craig, E. A., "The Heat-Shock Proteins," Annu. Rev. Genet., 22:631-677 (1988).
AX2	Welch, W. J. et al., "Biochemical Characterization of the Mammalian Stress Proteins and Identification of Two Stress Proteins as Glucose- and CA2+-Ionophore-regulated Proteins," J. Biol. Chem., 258(11):7102-7111 (1983)
AY2	Ardeshir, et al., "A 75 Kd Merozoite Surface Protein of Plasmodium Falciparum which is Related to the 70 kd Heat-Shock Proteins", EMBO J., 6(2):493-499 (1987).
AZ2	Vodkin, M.H. and Williams, J.C., "A Heat Shock Operon in Coxiella burnetii Produces a Major Antigen Homologous to a Protein in Both Mycobacteria and Escherichia coli", J. of Bacteriology, 170(3):1227-1234 (1988).
AR3	Thole, J.E.R., et al., "Antigenic relatedness of a strongly immunogenic 65 kDA mycobacterial protein antigen with a similarly sized ubiquitous bacterial common antigen", Microbial Pathogenesis, 4:71-83 (1988).
AS3	van Eden, W., et al., "Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis", Nature, 331(14):171-173 (1988).
АТ3	Del Guidice, G., et al., "Heat shock proteins as "super"-carriers for sporozoite peptide vaccines", Research in Immunol., 162:703-707 (1991).
AU3	Young, D.B., et al., "The 65kDa antigen of mycobacteria - a common bacterial protein?", Immunest Today, 8(7-8):215-219 (1987).
AV3	Shinnick, T.M., et al., "The Etiologic Agents of Leprosy and Tuberculosis Share an Immunoreactive protein Antigen with the Vaccine Strain Mycobacterium bovis BCG", Infect. and Immun., 55(8):1932-1935 (1987).
AW3	Kaufmann, S.H.E., et al., "Enumeration of T cells reactive with Mycobacterium tuberculosis organisms and specific for the recombinant mycobacterial 64-kDa protein", Eur. J. Immunol., 17:351-357 (1987).

EXAMINER	DATE CONSIDERED
,	

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	_
OT 1 1 7003 Coctober 10, 2003	APPLICANT Richard A. Young, et al.		
October 10, 2003  Use several sheets if necessary)	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AX3	Jindal, S., "Heat Shock Proteins: Applications in health and disease," Trends in Biotech., 14(1):17-20, 1996.
AY3	Suzue, K., et al., "Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway," Proc. Natl. Acad. Sci. USA, 94(24):13146-13151 (1997).
AZ3	Suzue, K. and Young R.A., "Adjuvant-Free hsp70 Fusion Protein System Elicits Humoral and Cellular Immune Responses to HIV-1 24 1," J. of Immunol., 156:873-879, (1996).
AR4	Verdegaal, E.M.E. et al., "Heat Shock Protein 65 Induces CD62e, CD106, and CD54 on Cultured Human Endothelial Cells and Increases Their Adhesiveness for Monocytes and Granulocytes," J. Immunol., 157:369-376 (1996).
AS4	Noll, A. and Autenrieti, I.B., "Immunity against Yersinia enterocolitica by Vaccination with Persinia HSP60 Immunostimulating Complexes or Yersinia HSP60 plus Interleukin-12," Infect. & Immon., 64:2955-2961 (1996).  Ferrero, R.L. et al., "The GroES homolog of Helicobacter pylori confers protective immunity against
AT4	Ferrero, R.L. et al., "The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice," Proc. Natl. Acad. Sci. USA, 92:6499-6503 (1995).
AU4	Gomez, F.J., et al., "Vaccination with Recombinant Heat Shock Protein 60 from Histoplasma capsulatum Protects Mice against Pulmonary Histoplasmosis," Infect. & Immun., 63:2587-2595 (1995).
AV4	Srivastava, P.K. and Udono, H., "Heat shock protein-peptide complexes in cancer immunotherapy," Curr. Opin. Immunol., 6:728-732 (1994).
AW4	DeNagel, D.C. and Pierce, S.K., "Heat Shock Proteins in Immune Responses," Crit. Rev. Imunol., 13(1):71-81 (1993).
AX4	Barrios, C. et al., "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEl and DnaK proteins requires cross-linking with antigen," Clin. Exp. Immunol., 98:229-233 (1994).
AY4	De Valesco, E.A., et al., "Synthetic Peptides Representing T-Cell Epitopes Act as Carriers in Pneumococcal Polysaccharide Conjugate Vaccines," Infect. & Immun., 63(3):961-968 (1995).

ΕΣ	KAMINER	DATE CONSIDERED
1		

PTO-1449 REPRODUCED  INFORMATION DISCLOSURE CITATION IN AN APPLICATION OCT 1003	ATTORNEY DOCKET NO. APPLICATION NO. 10/046,649		
	APPLICANT Richard A. Young, et al.		
October 10, 2003 (Use several sheets if necessary)	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AZ4	Könen-Waisman, S. et al., "Self and Foreign 60 Kilodation Heat Shock Protein T Cell Epitope Peptides Serve As Immunogenic Carriers for a T Cell-Independent Sugar Antigen," J. Immunol., 154:5977-5985 (1995).	
AR5	Friedland, J.S. et al., "Mycobacterial 65-kD heat shock protein induces release of proinflammatory cytokines from human monocytic cells," Clin. Exp. Immunol., 91:58-62 (1993).	
AS5	Huang, Q., et al., "In Vivo Cytotoxic T Lymphocyte Elicitation by Mycobacterial Heat Shock Protein 70 Fusion Proteins Maps to a Discrete Domain and Is CD4+ T Cell Independent," J. Exp. Med. 191(2):403-408 (January 17, 2000).	
AT5	Arrigo, A. and Welch, W.J., "Characterization and Purification of the Small 28,000-Dalton Mammalian Heat Shock Protein," J. Biol. Chem., 262(32):15359-15369 (1987).	
AU5	Catelli, M.G., et al., "The common 90-kd protein component of non-transformed '8S' steroid receptors is a heat-shock protein," EMBO J., 4(12):3131-3135 (1985).	
AV5	a heat-shock protein," EMBO J., 4(12):3131-3135 (1985).  Zylicz, M., et al., "The grpE Protein of Escherichia coli," J. Biol. Chem., 262(36):17437-17442 (1987).  Chandrasekhar, G.N., et al., "Purification and Properties of the groES Morphogenetic Protein of Scherichia Chem., 262(36):17437-17442 (1987).	
AW5	Zylicz, M., et al., "The grpE Protein of Escherichia coli," J. Biol. Chem., 262(36):17437-17442 (1987).  Chandrasekhar, G.N., et al., "Purification and Properties of the groES Morphogenetic Protein of Escherichia coli," J. Biol. Chem. 261(26):12414-12419 (1986).	
AX5	Zylicz, M. and Georgopoulos, C., "Purification and Properties of the Escherichia coli dnaK Replication Protein," J. Biol. Chem. 259(14):8820-8825 (1984).	
AY5	Welch, W.J. and Feramisco, J.R., "Purification of the Major Mammalian Heat Shock Proteins," J. Biol. Chem. 257(24):14949-14959 (1982).	
AZ5	Davis, B.D., et al., Microbiology, second edition, Harper & Row, Publishers, pp. 600 & 622.	
AR6	Doherty, et al., Evasion of host immune responses by tumours and viruses, "Vaccines against virally induced cancers", Wiley, Chicester (Ciba Foundation Symposium 187), pp. 245-260. See page 245, Abstract.	
AS6	Hird, et al., Immunotherapy with Monoclonal Antibodies, Genes and Cancer, Edited by Carney, et al., pp. 183-189, see page 185, first paragraph.	

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
INFORMATION DISCLOSURE CITATION ON AN APPLICATION	APPLICANT Richard A. Young, et al.		
October 10, 2003  October 10, 2003  October 10, 2003	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648

	EAU.	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
A	Т6	Oettgen, H.F. and Old, L.J., "Chapter 6: The History of Cancer Immunotherapy." In Biologic Therapy of Cancer, De Vita, V.T., Hellman, S. and Rosenberg, S.A., eds., (London: J.B. Lippincott) pp. 98-103 (1991).
Al	U6	Hudson, C.N., et al., "Active Specific Immunotherapy for Ovarian Cancer," The Lancet, 2:877-879 (1976, October 23).
A	.V6	Sparks, F.C., et al., "Immunology and Adjuvant Chemoimmunotherapy of Breast Cancer," Arch Surg, 111:1057-1062 (1976, October).
A	.W6	Humphrey, L.J., et al., "Adjuvant Immunotherapy for Melanoma," J. of Sur. Oncol., 25:303-305 (2984).
A	.X6	Hughes, L.E., et al., "A Study in Clinical Cancer Immunotherapy," Cancer, 26:269-278 (1970, August).
A	Υ6	Cassell, W.A., et al., "A Phase II Study on the Postsurgical Management of Stage Malignant Melanoma With a Newcastle Disease Virus Oncolysate," Cancer, 52:856-860 (1983, September).
A	Z6	Cassell, W.A., et al., "Viral Oncolysate in the Management of Malignant Melanoma, I. Preparation of the Oncolysate and Measurement of Immunologic Responses" Cancer, 40:672-679 (1977, August).
A	R7	Murray, D.R., et al., "Viral Oncolysate in the Management of Malignant Melanoma, II. Clinical Studies" Cancer, 40:680-686 (1977, August).
A	\S7	Srivastava, P.K., and Das, M.R., "The Serologically Unique Cell Surface Antigen of Zajdela Ascitic Hepatoma is Also Its Tumor-Associated Transplantation Antigen," Int. J. Cancer, 33:417-422 (1984).
А	AT7	Ullrich, S.J., et al., "A Mouse Tumor-Specific Transplantation Antigen is a Heat Shock-Related Protein," Proc. Natl. Acad. Sci., USA, 83:3121-3125 (1986, May).
A	NU7	Srivastava, P.K., et al., "Tumor Rejection Antigens of Chemically Induced Sarcomas of Inbred Mice," Proc. Natl. Acad. Sci., USA, 83:3407-3411 (1986, May).
A	AV7	Palladino, M.A., et al., "Expression of a Shared Tumor-Specific Antigen by Two Chemically Induced BALB/c Sarcomas," Cancer Research, 47:5074-5079 (1987, October).
А	 AW7	Srivastava, P.K. and Old, L.J., "Individually Distinct Transplantation Antigens of Chemically Induced Mouse Tumors," Immunology Today, 9:78-83 (1988, March).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
O P E FORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT Richard A. Young, et al.		
October 10, 2003 Use several sheets if necessary)	filing date January14, 2002	CONFIRMATION NO. 3487	GROUP 1648

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AX7	Srivastava, P.K. and Maki, R. G., "Stress-Induced Proteins in Immune Response to Cancer," Curr. Top. Microbiol. Immunol., 167:109-123 (1991).
AY7	Falk, R.E., et al., "Cell Mediated Immunity to Human Tumors," Arch. Surg., 107:261-265 (1973, August)
AZ7	McCulloch, P.B., et al., "Recurrent Malignant Melanoma: Effect of Adjuvant Immunotherapy on Survival," Can. Med. Assoc. J., 117:33-36 (1977, July).
AR8	Survival," Can. Med. Assoc. J., 117:33-36 (1977, July).  Haghbin, M., et al., "Immunotherapy with Oral BCG and Serial Immune Evaluation in Childhood Lymphoblastic Leukemia Following Three Years of Chemotherapy," Cancer, 46:2577-2586 (1980, December).
AS8	Pinskey, C.M., et al., "Intravesical Administration of Bacillus Calmette-Guérin in Patients With Recurrent Superficial Carcinoma of the Urinary Bladder: Report of a Prospective, Randomized Trail," Cancer Treat. Rep., 69:47-53 (1985, January).
AT8	Silverstein, A.M., "The History of Immunology," In Fundamental Immunology, 2nd Edition, Paul, W.E., ed., (NY:Raven Press), pp.21, 23-24 (1989).
AU8	Murphy, J.R. and Lefford, M.J., "Host Defenses in Murine Malaria: Induction of a Protracted State of Immunity with a Formalin-Killed Plasmodium berghei Blood Parasite Vaccine," Infec. Immun., 22:798-803 (1978).
AV8	Bertelli, M.S., et al., "BCG-Induced Resistance in Trypanosoma cruzi Experimental Infections," Tropenmed Parasitol, 32:93-96 (1981).
AW8	Jarecki-Black, J.C., et al., "The Effect of BCG-Vaccine Upon Experimental Visceral Leishmaniasis in Hampsters," Ann. Clin. Lab. Sci., 14:464-466 (1984).
AX8	Sturrock, R.F., et al., "Attempts to Induce Resistance to Schistosoma mansoni and S. haematobium in Kenyan Baboons (Papio anubis) Using Non-Specific Immunostimulants," Parasitology, 90:101-110 (1985).
AY8	Kimmig, P. and Wenk, P., "Suppression of Parasitaemia from Litomosoides carinii by Immunisation with BCG and Microfilariae," Z Parasitenkd, 67:317-327 (1982).
AZ8	Spencer, J.C., et al., "Nonspecific Protection of Mice against Influenza Virus Infection by Local or Systemic Immunization with Bacille Calmette-Guérin," J. Infect. Dis., 126:171-175 (1977).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
OF INFORMATION DISCLOSURE CITATION IN AN APPLICATION OCT 1 2003 (Use several sheets if necessary)	APPLICANT Richard A. Young, et al.		
	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AR9	Li, Z. and Srivastava, P.K., "Tumor Rejection Antigen gp96/grp94 is an ATPase: Implications for Protein Folding and Antigen Presentation," The EMBO Journal, 12(8):3143-3151 (1993).
AS9	Udono, H. and Srivastava, P.K., "Heat Shock Protein 70-associated Peptides Elicit Specific Cancer Immunity," J. Exp. Med., 178:1391-1396 (1993, October).
AT9	Welch, W.J. and Feramisco, J.R., "Rapid Purification of Mammalian 70,000-Dalton Stress Plateins: Affinity of the Proteins for Nucleotides," Mol. & Cell. Bio., 3:1229-1237 (1985).
AU9	DuBois, G.C., et al., "Isolation of a Tumor-Associated Transplantation Antigen (TATA) From an SV40-Induced Sarcoma. Resemblance to the TATA of Chemically Induced Neoplasms," Int. J. Cancer, 34:561-566 (1984).
AV9	La Thangue, N.B. and Latchman, D.S., "A Cellular Protein Related to Heat-Shock Protein 90 Accumulates during Herpes Simplex Virus Infection and Is Overexpressed in Transformed Cells," Experimental Cell Research, 178:169-179 (1988).
AW9	Rico, A.I., et al., "Characterization of the Immunostimulatory Properties of Leishmania infantum HSP70 by Fusion to the Escherichia coli Maltose-Binding Protein in Normal nu/nu BALB/c Mice," Infection and Immunity 66:347-352 (January 1998).
AX9	Butini, et al., "Comparative Analysis of HIV-Specific CTL Activity in Lymphoid Tissue and Peripheral Blood," J. Cell. Biochem., Suppl. 18B, Abstract J306 (1994).
AY9	Cohen, J., "Jitters Jeopardize AIDS Vaccine Trials," Science 262:980-981 (1993).
AZ9	Haynes, B.F., "Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development," Science 260:1279-1286 (1993).
AR10	Voellmy, et al., "Isolation and Functional Analysis of a Human 70,000-Dalton Heat Shock Protein Gene Segment," PNAS, 82:4949-4953 (1985).
AS10	Arnosti, et al., "Characterization of Heat Shock in <i>Bacillus subtilis</i> ," J. Bact. 168(3):1243-1249 (Dec. 1986).
AT10	Gomes, et al., "Heat Shock Protein Synthesis During Development in <i>Caulobacter crescentus</i> ," J. Bact. 168(3):923-930 (Nov. 1986).

EXAMINER	DATE CONSIDERED
i e	
1	

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
IN AN APPLICATION	APPLICANT Richard A. Young, et al.		
October 10, 2003  Use several sheets if necessary)	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648
& MADEWS.			

7480	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AU10	Layton, et al., "Induction of HIV-Specific Cytotoxic T Lymphocytes In Vivo With Hybrid HIV-1 V3: TVIVIUS-Like Particles," J. Immun. 151(2):1097-1107 (July 1993).
AV10	More, et al., "Activation of Cytotoxic T Cells In Vitro By Recombinant gp96 Fusion Proteins Prespective of the 'Fused' Antigenic Peptide Sequence," Immunology Letters 69:275-282 (1999).
AW10	Anthony, L.S.D., et al., "Priming of CD8+ CTL Effector Cells In Mice By Immunization With A Spess Protein-Influenza Virus Nucleoprotein Fusion Molecule," Vaccine 17:373-383 (1999).
AX10	Udono, H., et al., "Cellular Requirements For Tumor-Specific Immunity Elicited By Heat Shock Proteins: Tumor Rejection Antigen gp96 Primes CD8+ T Cells in vivo," Proc. Natl. Acad. Sci. USA 91:3077-3081 (April 1994).
AY10	Suto, R. and Srivastava, P.K., "A Mechanism for the Specific Immunogenicity of Heat Shock Protein-Chaperoned Peptides," Science 269:1585-1588 (September 15, 1995).
AZ10	Blachere, N.E., et al., "Heat Shock Protein-Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphocyte Response and Tumor Immunity," J. Exp. Med. 186(8):1315-1322 (October 20, 1997).
AR11	Tamura, Y., et al., "Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations," Science 278:117-120 (October 3, 1997).
AS11	Nair, S., et al., "Calreticulin Displays In Vivo Peptide-Binding Activity and Can Elicit CTL Responses Against Bound Peptides," J. Immun. 162:6426-6432 (1999).
ATII	Könen-Waisman, S. et al., "Self Heat-Shock Protein (hsp60) Peptide Serves in a Conjugate Vaccine against a Lethal Pneumococcal Infection," J. Infect. Diseases 179:403-413 (1999).
AU11	Schild, H., et al., "Stress Proteins and Immunity Mediated by Cytotoxic T Lymphocytes," Current Opinion in Immun.11:109-113 (1999).
AVII	Zhu, X., et al., "Structural Analysis of Substrate Binding by the Molecular Chaperone DnaK," Science 272:1606-1614 (June 14, 1996).
AW11	Jondal, M., et al., "MHC Class I-Restricted CTL Responses to Exogenous Antigens," Immunity 5:295-203 (October 1996).

n		
EXAMINER	DATE CONSIDERED	

PTO-1449 REPRODUCED ATTORNEY DOCKET NO. APPLICATION NO. 10/046,649 2869.1001-023 INFORMATION DISCLOSURE CITATION AN APPLICATION APPLICANT Richard A. Young, et al. OCT 1 & 2003 October 10, 2003 FILING DATE CONFIRMATION NO. SGROUP! e several sheets if necessary) January14, 2002 3487 1648()

& TRADE		
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
AS13	Roman, E., et al., "Synthetic Peptides non-Covalently Bound to Bacterial hsp 70 Elicit Reptide-Specific T-Cell Responses in vivo," Immunology 88:487-492 (1996).	
AT13	Geluk, A., et al., "Functional Analysis of DR17(DR3)-Restricted Mycobacterial T Cell Epitopes Reveals DR17-Binding Motif and Enables The Design of Allele-Specific Competitor Peptides," J. Immunology 149 (9):2864-2871 (November 1, 1992).	
AU13	Ciupitu, A.T., et al., "Immunization with a Lymphocytic Choriomeningitis Virus Peptide Mixed with Heat Shock Protein 70 Results in Protective Antiviral Immunity and Specific Cytotoxic T Lymphocytes," J. Exp. Med. 187 (5):685-691 (March 2, 1998).	
AV13	Horwitz, M.A., et al., "Protective Immunity Against Tuberculosis Induced by Vaccination With Major Extracellular Proteins of Mycobacterium tuberculosis," Microbiology 92:1530-1534 (February 1995).	
AW13	Matthews, R.C., et al., "Autoantibody to Heat-Shock Protein 90 Can Mediate Protection Against Systemic Candidosis," Immunology 74:20-24 (1991).	
AX13	Gelber, R.H., et al., "Vaccination With Pure Mycobacterium leprae Proteins Inhibits M. leprae Multiplication in Mouse Footpads," Infection and Immunity 62(10):4250-4255 (October 1994).	
AY13	Breloer, M., et al., "In Vivo and In Vitro Activation of T Cells After Administration of Ag-Negative Heat Shock Proteins," J. Immunol. 612:3141-3147 (1999).	
AZ13	Multhoff, G., et al., "The Role of Heat Shock Proteins in the Stimulation of an Immune Response," Biol. Chem. 379:295-300 (March 1998).	
AR14	Chen, W., et al., "Human 60-kDa Heat-Shock Protein: A Danger Signal to the Innate Immune System," J. Immunol. 162:3212-3219 (1999).	
AS14	Lehner, T., et al., "Heat Shock Proteins Generate ?-Chemokines Which Function as Innate Adjuvants Enhancing Adaptive Immunity," Eur. J. Immunol. 30:594-603 (2000).	
AT14	Grange, J.M., et al., "Tuberculosis and Cancer: Parallels in Host Responses and Therapeutic Approaches?," The Lancet 345:1350-1352 (1995).	
AU14	Amadori, M., et al., "Chaperonin 10 o fMycobacterium tuberculosis Induces a Protective Immune Response to Foot-and-Mouth Disease Virus," Arch Virol. 144:905-919 (1999).	
AV14	Dintzis, R.Z., "Rational Design of Conjugate Vaccines," Pediatric Research 32(4):376-385 (1992).	

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
INFORMATION DISCLOSURE CITATION S IN AN APPLICATION	APPLICANT Richard A. Young, et al.		
October 10, 2003  (Use several sheets if necessary)	FILING DATE January14, 2002	CONFIRMATION NO. 3487	group 1648

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AW14	Delmas, A., et al., "Studies of the Influence of Different Cross-Linking Reagents on the Immune Response against a B-Epitope," Bioconjugate Chemistry 3(1):80-84 (1992).
AX14	Response against a B-Epitope," Bioconjugate Chemistry 3(1):80-84 (1992).  Babbitt, et al., "Binding of Immunogenic Peptides to Ia Histocompatibility Molecules," Stature 317:359-361 (1985).
AY14	Brett, et al., "Differential Pattern of T Cell Recognition of the 65-kDA Mycobacterial Antison Following Immunization with the Whole Protein or Peptides, " Euro. J. Immunol. 19:1303-1310 (1989)
AZ14	Cox, et al., "Orientation of Epitopes Influences the Immunogenicity of Synthetic Peptide Dimers," Euro. J. Immunol. 18:2015-2019 (1988).
AR15	Engel, et al., "Generation of Antibodies Against Human hsp27 and Murine hsp25 by Immunization with a Chimeric Small Heat Shock Protein," Biomed. Biochim. Acta 50:1065-1071 (1991).
AS15	Francis, et al., "Peptide Vaccines Based on Enhanced Immunogenicity of Peptide Epitopes Presented with T-Cell Determinants or Hepatitis B Core Protein," Meth. Enzymol. 178:659-676 (1989).
AT15	Fyfe, et al., "Murine Immune Response to HIV-1 p24 Core Protein Following Subcutaneous, Intraperitoneal and Intravenous Immunization," Immunology 74:467-472 (1991).
AU15	Myers, "Role of B Cell Antigen Processing and Presentation in the Humoral Immune Response," FASEB J. 5:2547-2553 (1991).
AV15	Parker, "T-Cell Dependent B Cell Activiation," Annu. Rev. Immunol. 11:331-360 (1993).
AW15	Townsend, et al., "Antigen Recognition by Class I-Restricted T Lymphocytes," Ann. Rev. Immunol. 7:601-624 (1989).
AX15	Yewdell, et al., "The Binary Logic of Antigen Processing and Presentation to T Cells," Cell 62:203-206 (1990).
AY15	Agterberg, M., et al., "Outer Membrane PhoE Protein of Escherichia coli as a Carrier for Foreign Antigenic Determinants: Immunogenicity of Epitopes of Foot-and-Mouth Disease Virus," Vaccine 8:85-91 (February 1990).
AZ15	Agterberg, M., et al., "Outer Membrane Protein PhoE as a Carrier for the Exposure of Foreign Antigenic Determinants at the Bacterial Cell Surface," Antonie van Leeuwenhock 59:249-262 (1991).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED  INFORMATION DISCLOSURE CITATION  INFORMATION DISCLOSURE CITATION  OCT 1 OCT 10, 2003  Use several sheets if necessary)	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
	APPLICANT Richard A. Young, et al.		
	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AR16	Agterberg, M., et al., "Protection of Guinea-pigs Against Foot-and-Mouth Disease Virus by Immunization with a PhoeE FMDV Hybrid Protein," Vaccine 8:438-440 (October 1990).
AS16	Allen, P.M., et al., "T-Cell Recognition of Lysozyme: The Biochemical Basis of Presentation,"  Immunological Reviews 98:171-187 (1987).
AT16	Amory Siosson, L.M., et al., "Induction of Protective Immunity in Mice Using A 62-kDa Recombinant Fragment of a Schistosoma mansoni Surface Antigen," J. of Immunol., 149(11):3612-3630 (1992).
AU16	Bayliss, C.D., et al., "A Recombinant Fowlpox Virus That Expresses the VP2 Antigen of Infectious Bursal Disease Virus Induces Protection Against Mortality Caused by the Virus," Arch Virol. 120:193-205 (1991).
AV16	Billman-Jacobe, H., et al., "Mapping of the T and B Cell Epitopes of the Mycobacterium bovis Protein, MPB70," Immunol. Cell Biol. 68:359-365 (1990).
AW16	Blachere, N.E., et al., "Heat Shock Protein Vaccines Against Cancer," J. Immunotherapy 14(4):352-356 (1993).
AX 16	Brett, S.J., et al., "Influences of Antigen Processing on the Expression of the T Cell Repertoire," J. Exp. Med. 168:357-373 (July 1988).
AY16	Burrows, P.D., et al., "B-Cell Development in Man," Curr. Opinion Biol. 5:201-206 (1993).
AZ16	Cane, P.A., et al., "Reduction of Yellow Fever Virus Mouse Neurovirulence by Immunization with a Bacterially Synthesized Non-structural Protein (NS1) Fragment," J. Gen. Virol. 69:1241-1246 (1988).
AR17	Chong, P., et al., "Identification of a Potent Synthetic HIV1 Immunogen Comprising gag-P24 Tandem T-and B-Cell Epitopes," FEBS 264(2):231-234 (May 1990).
AS17	Ciborowski, P., et al., "Immunological response to a Staphylococcus aureus fibronectin-binding protein," J. Med. Microbiol., 37:376-381 (1992).
AT17	Clarke, B.E., et al., "Improved Immunogenicity of a Peptide Epitope After Fusion to Hepatitis B Core Protein," Nature 330:381-384 (November 1987).
AU17	Clarke, B.E., et al., "Presentation and immunogenicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria," J. of General Virology, 71:1109-1117 (1990).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED  PINFORMATION DISCLOSURE CITATION IN AN APPLICATION October 10, 2003	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
	APPLICANT Richard A. Young, et al.		
October 10, 2003 Use several sheets if necessary)	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AV17	Clough, E.R., et al., "Production of Anti-Sporozoite Antibodies in Absence of Response to Carrier By Coupling an MDP Derivative to a Malaria Peptide-Tetanus Toxoid Conjugate," Biochemical and Biophysical Research Communications, 131(1):70-75 (1985).		
AW17	Clough, E.R., et al., "Production of Anti-Sporozoite Antibodies in Absence of Response to Carrier By Coupling an MDP Derivative to a Malaria Peptide-Tetanus Toxoid Conjugate," Biochemical and Biophysical Research Communications, 131(1):70-75 (1985).  Crane, M.S., et al., "Cross-Protection Against Four Species of Chicken Coccidia with a Smale Recombinant Antigen," Infection and Immunity 59(4):1271-1277 (April 1991).  Decision Revoking European Patent EP-B-0419569.		
AX 17	Decision Revoking European Patent EP-B-0419569.		
AY17	European Patent No. 0700445 B1; Opposition By Antigenics, Inc.: Statement of Grounds of Opposition.		
AZ17	Drew, M.D., et al., "Vaccination By Cholera Toxin Conjugated to a Herpes Simplex Virus Type 2 Glycoprotein D Peptide," J. General Virol. 73:2357-2366 (1992).		
AR18	Emmrich, F., et al., "A Recombinant 64 Kilodalton Protein of Mycobacterium bovis Bacillus Calmette-Guerin Specifically Stimulates Human T4 Clones Reactive to Mycobacterial Antigens," J. Exp. Med. 163:1024-1029 (April 1986).		
AS18	Etlinger, H.M., et al., "Antibody Responses to a Synthetic Peptide-Based Malaria Vaccine Candidate: Influence of Sequence Variants of the Peptide," Eur. J. Immunol. 21:1505-1511 (1991).		
AT18	Finnegan, A., et al., "The T Cell Repertoire For Recognition of a Phylogenetically Distant Protein Antigen - Peptide Specificity and MHC Restriction of Staphylococcal Nuclease-specific T Cell Clones," J. Exp. Med. 164:897-910 (September 1986).		
AU18	Francis, M.J., et al., "Non-Responsiveness to a Foot-and-Mouth Disease Virus Peptide Overcome by Addition of Foreign Helper T-Cell Determinants," <i>Nature 330</i> :168-170 (November 1987).		
AV18	Freimuth, P., et al., "Insertion of Myoglobin T-Cell Epitopes Into the Escherichia coli Alkaline Phosphatase," Res. Microbiol. 141:995-1001 (1990).		
AW18	Fuqua, S.A.W., et al., "Induction of the Estrogen-regulated "24K" Protein by Heat Shock," Cancer Research 49:4126-4129 (August 1, 1989).		
AX 18	Gammon, G., et al., "The Choice of T-Cell Epitopes Utilized on a Protein Antigen Depends on Multiple Factors Distant from, as well as at the Determinant Site," <i>Immunological Reviews</i> 98:53-73 (1987).		

EXAMINER	DATE CONSIDERED	$\neg$
		l ii
1		II.

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
October 10, 2003  October 10, 2003  October 10, 2003	APPLICANT Richard A. Young, et al.		
	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AY18	Good, M.F., et al., "Construction of Synthetic Immunogen: Use of New T-Helper Epitope on Malaria Circumsporozoite Protein," Science 235:1059-1062 (February 1987).
AZ18	Handman, E., et al., "Leishmania major: Production of Recombinant gp63, Its Antigenicity and Immunogenicity in Mice," Experimental Parasitology 70:427-435 (1990).
AR19	Hinuma, S., et al., "A Novel Strategy For Converting Recombinant Viral Protein Into High Immunogenic Antigen," FEBS 288(1,2):138-142 (August 1991).
AS19	Hogervorst, E.M., et al., "Efficient Recognition by Rat T Cell Clones of an Epitope of Mycobacterial hsp 65 Inserted in Escherichia coli Outer Membrane Protein PhoE," Eur. J. Immunol. 20:2763-2768 (1990).
AT19	Janvier, B., et al., "Immune Response to a Major Epitope of p24 During Infection with Human Immunodeficiency Virus Type 1 and Implications for Diagnosis and Prognosis," J. Clinical Microbiol. 29(3):488-492 (March 1991).
AU19	Jarrett, W.F.H., et al., "Studies on Vaccination against Papillomaviruses: Prophylactic and Therapeutic Vaccination with Recombinant Structural Proteins," Virology, 184:33-42 (1991).
AV19	Jin, X.W., et al., "Bovine Serological Response to a Recombinant BPV-1 Major Caspid Protein Vaccine," Intervirology 31:345-354 (1990).
AW19	Johnston, J.M., et al., "Antigenic and Immunogenic Properties of a Hepatitis A Virus Capsid Protein Expressed in Escherichia coli," J. Infect. Diseases 157(6):1203-1211 (June 1988).
AX 19	Kazura, J.W., et al., "Protective Efficacy of a Cloned Brugia malayi Antigen in a Mouse Model of Microfilaremia," J. Immunol. 145(7):2260-2264 (October 1990).
AY19	Kit, M., et al., "Bovine Herpesvirus-1 (Infectious Bovine Rhinotracheitis Virus)-Based Viral Vector Which Expresses Foot-and-Mouth Disease Epitopes," <i>Vaccine 9</i> : 564-572 (August 1991).
AZ19	Knapp, B., et al., "A Histidin Alanine Rich Recombinant Antigen Protects Actus Monkeys from P. Falciparium Infection," Behring Inst. Mitt.82:349-359 (1988).
AR20	Krzych, U., et al., "Repertoires of T Cells Directed Against A Large Protein Antigen, β-Galactosidase," J. Immunol. 128(4):1529-1534 (April 1982).
AS20	Lamb, J.R., et al., "Mapping of T Cell Epitopes Using Recombinant Antigens and Synthetic Peptides," The EMBO J. 6(5):1245-1249 (1987).

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED ATTORNEY DOCKET NO. APPLICATION NO. 2869.1001-023 10/046,649 INFORMATION DISCLOSURE CITATION IN AN APPLICATION APPLICANT Richard A. Young, et al. October 10, 2003 FILING DATE CONFIRMATION NO. GROUP Use several sheets if necessary) January14, 2002 3487 1648

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AT20	Lamb, F.I., et al., "Heterologous Expression of the 65-Kilodalton Antigen of Mycobacterium leprae and Murine T-Cell Responses to the Gene Product," Infection and Immunity 56(5):1237-1241 (May 1988).
AU20	Lawrence, R.M., et al., "Expression of the Cloned Gene for Enterotoxin Stb of Escherichia Contain Infection and Immunity, 58(4):970-977 (1990).
AV20	Leclerc, C., et al., "A Synthetic Vaccine Constructed by Copolymerization of B and T Cell Determinants," Eur. J. Immunol. 17:269-273 (1987).
AW20	Lee, A.C.J., et al., "A Method for Preparing β-hCG Cooh Peptide-Carrier Conjugates of Bredictable Composition," Molecular Immunology, 17:749-756 (1980).
AX 20	Lehner, T., et al., "Identification of T- and B-CellEpitopes in Synthetic Peptides Derived From a Streptococcus Mutans Protein and Characterization of Their Antigenicity and Immunogenicity," Archs oral Biol. 35, Suppl.:39S-45S (1990).
AY20	Linsley, P.S., et al., "T-Cell Antigen CD28 Mediates Adhesion With B Cells By Interacting With Activation Antigen B7/BB-1," Proc. Natl. Acad. Sci. USA 87:5031-5035 (July 1990).
AZ20	Löwenadler, B., et al., "T and B Cell Responses To Chimeric Proteins Containing Heterologous T Helper Epitopes Inserted At Different Positions," <i>Molecular Immunology</i> 29(10):1185-1190 (1992).
AR21	Löwenadler, B., et al., "Enhanced Immunogenicity of Recombinant Peptide Fusions Containing Multiple Copies of a Heterologous T Helper Epitope," Eur. Immunol. 20:1541-1545 (1990).
AS21	Löwenadler, B., et al., "A recombinant Escherichia coli heat-stable enterotoxin (Sta) fusion protein eliciting anti-STa neutralizing antibodies," FEMS Microbiology Letters, 82:271-277 (1991).
AT21	McKenzie, K.R., et al., "Sequence and Immunogenicity of the 70-kDa Heat Shock Protein of Mycobacterium leprae," J. Immunol. 147(1):312-319 (July 1991).
AU21	Mehra, V., et al., "Efficient Mapping of Protein Antigenic Determinants," Proc. Natl. Acad. Sci. USA 83:7013-7017 (September 1986).
AV21	Merrick, R.M., et al., "The Use of β-Galactosidase Fusion Proteins Encoding the Early Region 1 Transforming Proteins of Adenovirus Type 12 to Examine the Humoral Response in Tumor-Bearing Animals," J. Gen. Virol. 72:955-960 (1991).

EXAMINER	DATE CONSIDERED	II
1		l.

PTO-1449 REPRODUCED  PTO-1449 REPRODUCED  PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
IN AN APPLICATION	APPLICANT Richard A. Young, et al.		
October 10, 2003  (Use several sheets if necessary)	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648
TE TRADE			

A THAO	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
AW21	Miller, G.A., et al., "Characterization and Vaccine Potential of a Novel Recombinant Coccidial Antigen," Infection and Immunity, 57(7):2014-2020 (1989).	
AX 21	Moore, S.K., et al., "Murine 86- and 84-kDa Heat Shock Proteins, cDNA Sequences, Chromosome Assignments, and Evolutionary Origins," J. Biol. Chem. 264(10):5343-5351 (1989).	
AY21	Moore, S.K., et al., "Murine 86- and 84-kDa Heat Shock Proteins, cDNA Sequences, Chronosome Assignments, and Evolutionary Origins," J. Biol. Chem. 264(10):5343-5351 (1989).  Morgan, D.O., et al., "Protection of Cattle and Swine Against Foot-and-Mouth Disease, Using Biosynthetic Peptide Vaccines," Am. J. Vet. Res. 51(1):40-45 (January 1990).	
AZ21	Morimoto, R.I., "Cells in Stress: Transcriptional Activation of Heat Shock Genes," Science 29:1409-1410 (March 1993).	
AR22	Moser, D., et al., "The Humoral Response to Heat Shock Protein 70 in Human and Murine Schistosomiases mansoni," Parasite Immunol. 12:341-352 (1990).	
AS22	Oberg, L.A., et al., "Bacterially Expressed Nucleoprotein of Infectious Hematopoietic Necrosis Virus Augments Protective Immunity Induced by the Glycoprotein Vaccine in Fish," J. Virol. 65:4486-4489 (August 1991).	
AT22	Oftung, F., et al., "Human T Cell Clones Recognize Two Abundant Mycobacterium tuberculosis Protein Antigens Expressed in Escherichia coli," J. Immunol. 138(3):927-931 (February 1987).	
AU22	Owens, T., et al., "The Cell Biology of T-dependent B Cell Activation," Leucocytes: Functions and Pathogenesis, Biochem. Cell Biol.67:481-489 (1989).	
AV22	Partidos, C.D., et al., "Immune Responses in Mice Following Immunization With Chimeric Synthetic Peptides Representing B and T Cell Epitopes of Measles Virus Proteins," J. Gen. Virol. 72:1293-1299 (1991).	
AW22	Peeters, J.M., et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," J. of Immunol. Methods, 120:133-143 (1989).	
AX 22	Phalipon, A., et al., "Expression of a poliovirus type 1 neutralization epitope on a diphtheria toxin fusion protein," <i>Vaccine</i> , 7:132-136 (1989).	
AY22	Rand, K.N., et al., "Cloning and Expression of a Protective Antigen from the Cattle Tick Boophilus microplus," Proc. Natl. Acad. Sci. USA 86:9657-9661 (December 1989).	

EXAMINER	DATE CONSIDERED

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION October 10, 2003	APPLICANT Richard A. Young, et al.		
October 10, 2003  (Use several sheets if necessary)	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AZ22	Rickard, M.D., "Cestode Vaccines," Southeast Asian J. Trop. Med Public Health, 32: 287-290.
AR23	Rossi-Campos, A., et al., "Immunization of pigs against Actinobacillus pleuropneumonice with two recombinant protein preparations," Vaccine, 10(8):512-518 (1992).
AS23	Rothbard, J.B., et al., "A Sequence Pattern Common to T Cell Epitopes," The EMBO J. 7(1993-100 (1988).
AT23	Sad, S., et al., "Bypass of Carrier-Induced Epitope-Specific Suppression Using a T-Helper Epitope," Immunology 76:599-603 (1992).
AU23	Schödel, F., et al., "Synthesis in Vibrio cholerae and Secretion of Hepatitis B Virus Antigens Fused to Escherichia coli Heat-Labile Entertoxin Subunit B," Gene 99:255-259 (1991).
AV23	Smith, D.B., et al., "M <sub>r</sub> 26,000 antigen of Schistosoma japonicum recognized by resistant WEHI 129/J mice is a parasite glutathione S-transferase," Proc. Natl. Acad. Sci. USA 83:8703-8707 (1986).
AW23	Spindler, K.R., et al., "Analysis of Adenovirus Transforming Proteins from Early Regions 1A and 1B with Antisera to Inducible Fusion Antigens Produced in <i>Escherichia coli</i> ," <i>J. Virol.</i> 49(1):132-141 (January 1984).
AX 23	Ståhl, S., et al., "A Dual Expression System for the Generation, Analysis and Purification of Antibodies to a Repeated Sequence of the <i>Plasmodium falciparum</i> Antigen Pf155/RESA," <i>J. Immunological Methods</i> 124:43-52 (1989).
AY23	Su, G., et al., "Extracellular export of Shiga toxin B-subunit/haemolysin A (C-terminus) fusion protein expressed in Salmonella typhimurium aroA-mutant and stimulation of B-subunit specific antibody responses in mice," Microbial Pathogenesis, 13:465-476 (1992).
AZ23	Suzue, K., et al., "Heat Shock Proteins as Immunological Carriers and Vaccines," Stress-Inducible Cellular Responses (U. Feige, R. I. Morimoto, I. Yahara, B. S. Polla, eds.), Birkhauser/Springer, 77: 451-465 (1996).
AR24	Talwar, G.P., et al., "Enhancement of antigonadotropin response to the $\beta$ -subunit of ovine luteinizing hormone by carrier conjugation and combination with the $\beta$ -subunit of human chorionic gonadotropin," Fertility and Sterility, 46(1):120-126 (1986).

T		
EXAMINER	DATE CONSIDERED	
	DATE CONSTRUE	11
ll .		

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 2869.1001-023	APPLICATION NO. 10/046,649	
NATION DISCLOSURE CITATION AN APPLICATION	APPLICANT Richard A. Young, et al.		
October 10, 2003 (Us several sheets if necessary)	FILING DATE January14, 2002	CONFIRMATION NO. 3487	GROUP 1648
TO TRADEWAY			

PAO	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AX11	Bennett, S.R.M., et al., "Help for Cytotoxic-T-cell Repsonses is Mediated by CD40 Signalling," Nature 393:478-480 (June 4, 1998).
AY11	Schoenberger, S.P., et al., "T-cell Help for Cytotoxic T Lymphocytes is Mediated by CD40-CD40L Interactions," Nature 393:480-483 (June 4, 1998).
AZII	Hunt, C. and Calderwood, S., "Characterization and Sequence of a Mouse hsp70 Gene and Its Expression in Mouse Cell Lines," Gene 87:199-204 (1990).
AR12	Flaherty, K., et al., "Three-dimensional Structure of the ATPase Fragment of a 70K Heat-Shock Cognate Protein," Nature 346:623-628 (August 16, 1990).
AS12	Chen, W., et al., "Human 60-kDa Heat-Shock Protein: A Danger Signal to the Innate Immune System," J. of Immun. 162:3212-3219 (1999).
AT12	Kol, A., et al., "Chlamydial and Human Heat Shock Protein 60s Activate Human Vascular Endothelium, Smooth Muscle Cells, and Macrophages," J. Clin. Invest. 103:571-577 (1999).
AU12	Hawiger, J., "Noninvasive Intracellular Delivery of Functional Peptides and Proteins," J. Curr. Opin. Chem. Biol. 3:89-94 (1999).
AV12	Lindgren, M., et al., "Cell-Penetrating Peptides," TiPS 21(3):99-103 (March 2000).
AW12	Morris, M.C., et al., "Translocating Peptides and Proteins and Their Use for Gene Delivery," Curr. Opin. Biotechnol. 11(5):461-466 (October 2000).
AX12	Schwarze, S.R., et al., "Protein Transduction: Unrestricted Delivery Into All Cells?," Trends Cell Biol. 10(7):290-295 (July 2000).
AY12	Gariepy, J., et al., "Vectorial Delivery of Macromolecules Into Cells Using Peptide-Based Vehicles," Trends Biotechnol. 19(1):21-28 (2001).
AZ12	Rost, B., "Twilight Zone of Protein Sequence Alignments," Protein Engineering 12(2):85-94 (1999).
AR13	Vogt, G., et al., "An Assessment of Amino Acid Exchange Matrices In Aligning Protein Sequences: The Twilight Zone Revisited," J. Molec. Biol. 249:816-831 (1995).

EXAMINER	DATE CONSIDERED	
	Jiii Condibands	
II .		
li .		

PTO-1449 REPRODUCED APPLICATION NO. ATTORNEY DOCKET NO. 2869.1001-023 10/046,649 INFORMATION DISCLOSURE CITATION IN AN APPLICATION APPLICANT Richard A. Young, et al. October 10, 2003 FILING DATE CONFIRMATION NO. GROUP January14, 2002 (Use several sheets if necessary) 3487 1648

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AS24	Tetzlaff, C.L., et al., "Induction of Proliferative Responses of T Cells from Babesia Bovis-Immunity attle with a Recombinant 77-Kilodalton Merozoite Protein (Bb-1)," Infection and Immunity 60(2) 644-652 (1992).
AT24	Thanavala, Y.M., et al., "Affinity, cross-reactivity and biological effectiveness of rabbit antibodes against a synthetic 37 amino acid C-terminal peptide of human chorionic gonadotrophin, Exp. Immunol., 39:112-118 (1980).
AU24	Thole, J.E.R., et al., "Use of Recombinant Antigens Expressed in Escherichia coli K-12 To Map B-Cell and T-Cell Epitopes on the Immunodominant 65-Kilodalton Protein of Mycobacterium bovis BCG," Infection and Immunity 56(6):1633-1640 (June 1988).
AV24	Tommassen, J., et al., "Molecular Analysis of the Promoter Region of the Escherichia coli K-12 phoE Gene - Identification of an Element, Upstream from the Promoter, Required for Efficient Expression of PhoE Protein," Mol. Biol. 198:633-641 (1987).
AW24	Udono, H., et al., "Comparison of Tumor-Specific Immunogenicities of Stress-Induced Proteins gp96, hsp90, and hsp70," J. Immunol. 152: 5398 - 5403 (Jun 1994).
AX 24	Ullrich, S.J., et al., "Transcriptional and Translational Analysis of the Murine 84- and 86-kDa Heat Shock Proteins," J. Biol. Chem. 264(12):6810-6816 (1989).
AY24	Vreden, S.G.S., et al., "Phase I Clinical Trial of a Recombinant Malaria Vaccine Consisting of the Circumsporozoite Repeat Region of Plasmodium Falciparum Coupled to Hepatitis B Surface Antigen," Am. J. Trop. Med. Hyg., 45(5):533-538 (1991).
AZ24	Xu, L., et al., "Epitope Mapping and Characterization of the Infectious Hematopoietic Necrosis Virus Glycoprotein, Using Fusion Proteins Synthesized in <i>Escherichia coli</i> ,", <i>J. Virol.</i> 65(3):1611-1615 (March 1991).
AR25	Zavala, F., et al., "Synthetic Peptide Vaccine Confers Protection Against Murine Malaria," J. Exp. Med., 166:1591-1596 (1987).
AS25	November 2000 Printout of a Web Page of Stressgen Biotechnologies (http://stressgen.com).

EXAMINER	DATE CONSIDERED
	DATE CONGIDENCE
il de la companya de	<b> </b>
II .	I